Browsing Tag
DRL
Big Movers on D-St: What should investors do with MindTree, DRL and KEC International?
The Indian market closed in the red for the third consecutive day on Wednesday. The S&P BSE Sensex fell by nearly 400 points while the Nifty50 closed below 16,000 levels.
Sectorally, buying was seen in healthcare, FMCG, metals, and the…
Stocks in the news: TCS, Power Grid, DRL, 5Paisa, Tata Motors and Dmart
Nifty futures on the Singapore Exchange traded 20 points, or 0.12 per cent lower at 16,207.5, signaling that Dalal Street was headed for a positive start on Monday. Here are a dozen stocks which may buzz the most in today's trade:
Spandana…
Eton Pharma : DRL acquires injectable portfolio from US-based Eton Pharma for $50 million
Dr. Reddy’s on Friday announced that it has acquired a portfolio of branded and generic injectable products from
Deer Park, Illinois, based Eton Pharmaceuticals. Under the terms of the agreement, Dr. Reddy’s will pay $5 million upfront in…
Kunal Bothra’s market outlook & two stock picks for next week
Friday’s move compliments data points on the indices. We also saw a blend of short covering as well as long built up so there were so many large cap names which looked more formidable likes of , Dr Reddy making a comeback, the pharma stocks…
Sensex ekes out 86-pt gain after choppy trade; Nifty tops 16,600
nifty: Sensex ekes out 86-pt gain after choppy trade; Nifty tops 16,600 - The Economic Times Video | ET Now ET Now | 11 Mar 2022, 03:52 PM ISTCLOSING BELL: Sensex ekes out 86-pt gain after choppy trade; Nifty tops 16,600; Sun Pharma, DRL…
DRL net rises to ₹709 cr. as impairment declines
Pharma major Dr. Reddy’s Laboratories reported consolidated net profit surged to ₹709.3 crore in the December quarter on improved sales in mainstay generics and a sharp decline in impairment charges compared with a year earlier.Profit was…
Dr. Reddy’s, Prestige BioPharma ink pact on cancer drug
DRL gets rights to commercialise proposed trastuzumab biosimilar in select LatAm, S-E Asia markets.
Pharma major Dr. Reddy’s Laboratories has entered into a partnership with Prestige BioPharma under which it will get exclusive rights…
India’s vaccination drive picks up for adults but long road ahead for children
Covaxin phase 2/3 studies have been completed for 2 to 17 years age group population and immunogenicity and safety data have been submitted to the Drugs Controller General of India (DCGI) for further approvals.Even as India’s cumulative…